[subscription] Repligen acquired BioLife, a Bothell-based cell and gene therapy tools maker, for $1.5B ($11.25 cash plus 0.1442 shares per BioLife share), expected to close in Q4.. BioLife. Fwd: Women Are Losing Ground to AI Faster Than Men

[alert] Even Healthcare is in talks to raise approximately $50 million in a Series B funding round led by Khosla Ventures at a valuation of about $300 million, with participation from Alpha Wave Global.. Even Healthcare. Google Alert - Khosla Ventures

KKR portfolio company. Asset class: Private Equity. Industry: Healthcare. Region: Americas.

Suite 401 | Medical Office: 5901 W Olympic Blvd. Suite 401 Los Angeles, CA 90036 ... Access your lab results, request prescription refills, request appointments, exchange messages with our Medical Office | LifeFlow: Case Summary A 32-year-old G1P0 female developed severe postpartum hemorrhage following prolonged induction of labor, ultimately requiring cesarean delivery. Her estimated intraoperative blood loss was approximately 1200mL, and in the immediate postoperative period she developed... | Suite 401 Medical | LinkedIn: Report this company · Website · https://www.suite401.com/ External li

[subscription] AdvanCell, a clinical-stage radiopharmaceutical company developing targeted alpha therapies for cancer, received a $315 million Series D led by Ally Bridge Group and Alpha Wave.. AdvanCell. Fwd: Stripe and Advent's lowball bid

Aethlon Medical, Inc. (AEMD): Two of three cohorts in our Hemopurifier oncology clinical trial have been completed, with no safety concerns reported by the Data Safety Monitoring Board | Aethlon Medical, Inc. - AnnualReports.com: Aethlon Medical (NASDAQ: AEMD) is <strong>focused on addressing unmet needs in global health and biodefense</strong>. The Aethlon Hemopurifier® is a first-in-class therapeutic device designed to address life-threatening viral infections. | Company Information :: Aethlon Medical, Inc. (AEMD): Aethlon Medical <strong>develops immunotherapeutic technologies to combat can